Under the terms of the agreement, research targets will be determined by a steering committee composed of leading scientists at University of California, San Francisco (UCSF), including Lewis Lanier, professor and vice chair for department of microbiology and immunology; Jeffrey Bluestone, director of UCSF Diabetes Center; and Susan Fisher, professor, department of cell and tissue biology.
The committee will direct research into antibodies for cancer targets, stem cell surface markers and autoimmune disease targets. The university will have free access to the antibodies resulting from the partnership for its ongoing immunology and disease research.
David Smoller, president of research biotech business unit at Sigma-Aldrich, said: “By partnering with the highly regarded UCSF research team, Sigma-Aldrich is helping to further promote the study of a number of important cancer targets, regenerative medicine applications and neglected diseases.”